Lancet Respiratory Medicine

Article	Citations
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study	6560
Pathological findings of COVID-19 associated with acute respiratory distress syndrome	5851
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?	1931
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations	989
COVID-19 cytokine storm: the interplay between inflammation and coagulation	858
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans	856
Rational use of face masks in the COVID-19 pandemic	842
Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017	780
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy	674
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial	666
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes	582
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study	543
The future of cystic fibrosis care: a global perspective	477
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study	448
Protecting health-care workers from subclinical coronavirus infection	413
COVID-19 and the impact of social determinants of health	411
Sex difference and smoking predisposition in patients with COVID-19	393
Management of acute kidney injury in patients with COVID-19	392
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial	385
SARS-CoV-2 viral load predicts COVID-19 mortality	384
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures	374
Particle sizes of infectious aerosols: implications for infection control	370
Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases	361
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study	349
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial	343

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study	337
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study	336
Pulmonary fibrosis secondary to COVID-19: a call to arms?	335
Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities	332
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?	326
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity	314
Human recombinant soluble ACE2 in severe COVID-19	305
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial	302
Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19	299
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study	295
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	286
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controll	279
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial	278
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?	267
New variant of SARS-CoV-2 in UK causes surge of COVID-19	265
Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study	262
Tracheostomy in the COVID-19 era: global and multidisciplinary guidance	261
Staff safety during emergency airway management for COVID-19 in Hong Kong	257
Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission	255
Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics	251
False-positive COVID-19 results: hidden problems and costs	242
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial	242
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers	240
WHO global progress report on tuberculosis elimination	240
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data	236
NICE guideline on long COVID	230
COVID-19 outbreak: less stethoscope, more ultrasound	219
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society	217
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study	215
COVID-19: a heavy toll on health-care workers	211
Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study	211
Treatment for severe acute respiratory distress syndrome from COVID-19	210
Functional effects of the microbiota in chronic respiratory disease	210
Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a rand	208
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial	205
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial	197
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicent	195
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	195
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial	193
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials	192
COVID-19, ECMO, and lymphopenia: a word of caution	192
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial	185
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform	183
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial	179
Omicron variant and booster COVID-19 vaccines	177
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial	174
Understanding pathways to death in patients with COVID-19	173
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	171
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities	168
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study	167

Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicen	167
Systemic sclerosis-associated interstitial lung disease	159
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study	158
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial	157
E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach	157
Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries	155
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study	154
Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database	153
Primary ciliary dyskinesia in the genomics age	153
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, contr	152
Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study	144
SARS-CoV-2 evolution and vaccines: cause for concern?	144
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial	140
Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses	135
Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials	134
Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations	134
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial	132
Respiratory support for patients with COVID-19 infection	131
Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?	129
Immunomodulation in COVID-19	129
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study	128
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an ope	126
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial	125
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study	123
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis	120
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study	119
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study	118
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	117
COVID-19 infection in children	111
Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis	108
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial	108
Tobacco smoking and COVID-19 infection	108
Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial	107
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study	107
Coronavirus in China	103
COVID-19 transmission—up in the air	103
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial	102
Subphenotypes in critical care: translation into clinical practice	101
Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19	101
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study	101
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controll	101
Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies	101
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Character	100
Impact of COVID-19 on people with cystic fibrosis	100
Respiratory health in athletes: facing the COVID-19 challenge	99
Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient	98
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial	97
The Russian vaccine for COVID-19	97
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study	96
Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study	95
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities	95
Chronic respiratory diseases: a global view	93
Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data	93
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial	93
Major differences in ICU admissions during the first and second COVID-19 wave in Germany	92
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	92
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation	91
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?	91
Implications of the second wave of COVID-19 in India	90
Immunotherapies for COVID-19: lessons learned from sepsis	90
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties	90
Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a random	88
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study	88
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled pha	87
Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis	87
COVID-19 interstitial pneumonia: monitoring the clinical course in survivors	86
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial	86
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	85
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial	85
Interleukin-6: obstacles to targeting a complex cytokine in critical illness	85
Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus	84
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base	84
When to consider lung transplantation for COVID-19	83
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (AND	82
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study	81
Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-a	81
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	79
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial	78
Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database	78
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, par	78

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis	77
Lifting of COVID-19 restrictions in the UK and the Delta variant	77
Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study	76
Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial	76
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial	76
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-labe	76
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study	74
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controll	73
Adoption of COVID-19 triage strategies for low-income settings	73
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context	73
Saliva as a gold-standard sample for SARS-CoV-2 detection	73
Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study	73
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis	72
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study	72
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial	72
Corticosteroids for COVID-19: the search for an optimum duration of therapy	71
Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study	71
Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial	70
Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial	69
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase	69
Monitoring the COVID-19 epidemic in the context of widespread local transmission	69
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial	68
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions	68
The genetics of asthma and the promise of genomics-guided drug target discovery	68
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment	67
Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks	67
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease	66
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial	66
The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?	65
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial	65
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial	65
COVID-19: the need for continuous medical education and training	65
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial	64
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials	64
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study	64
The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions	64
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial	63
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study	63
SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors	62
Challenges in lung cancer therapy during the COVID-19 pandemic	62
Coronavirus epidemic: preparing for extracorporeal organ support in intensive care	62
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK	62
Use of non-invasive ventilation for patients with COVID-19: a cause for concern?	62
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis	62
Antihypertensive drugs and risk of COVID-19?	61
COVID-19 among people experiencing homelessness in England: a modelling study	61
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study	60
Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study	59
Effect of a fluid bolus on cardiovascular collapse among critically ill adults undergoing tracheal intubation (PrePARE): a randomised controlled trial	58
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	58
Advances in understanding and reducing the burden of severe asthma in children	58
COVID-19 in Nigeria: a disease of hunger	58
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial	58
Advancing precision medicine for acute respiratory distress syndrome	57
Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort	56
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study	56
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine	55
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study	55
Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts	55
Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts	55
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies	55
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study	54
The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study	54
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan	54
Use of facemasks during the COVID-19 pandemic	54
Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation	54
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial	54
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	54
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019	53
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers	53
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial	53
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled	53
Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial	52
A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study	51
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial	50
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	50
The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda	50
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion	50
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study	50
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	50
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials	50
Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis	50
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study	49
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial	49
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	48
Lung function testing in the COVID-19 endemic	48
Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis	47
Delayed-onset myocarditis following COVID-19	47
Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study	47
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: resul	47
Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?	47
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations	46
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study	46
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study	46
COVID-19 hospital admissions: Brazil's first and second waves compared	45
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management	45
A 5-point strategy for improved connection with relatives of critically ill patients with COVID-19	45
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	44
Extracorporeal membrane oxygenation for COVID-19 during first and second waves	44
Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?	43
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, doubl	43
Kidney transplant programmes during the COVID-19 pandemic	43
Toning down the 2019-nCoV media hype—and restoring hope	43
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial	42
Could a good night's sleep improve COVID-19 vaccine efficacy?	41
The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis	41
Efforts escalate to protect homeless people from COVID-19 in UK	41
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study	41
Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial	41
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	41
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials	41
The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study	40
α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action	40
Expression quantitative trait locus fine mapping of the 17q12–21 asthma locus in African American children: a genetic association and gene expression study	40
Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group	39
Imaging research in fibrotic lung disease; applying deep learning to unsolved problems	39
Immunomodulation by macrolides: therapeutic potential for critical care	39
Asthma in children during the COVID-19 pandemic: lessons from lockdown and future directions for management	39
Repurposing drugs for treatment of COVID-19	39
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial	39
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	39
Non-invasive respiratory support strategies in COVID-19	38
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study	38
Small airway loss in the physiologically ageing lung: a cross-sectional study in unused donor lungs	38
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities	38
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study	38
Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study	38
Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study	37
The changing demographics of COVID-19	37
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial	36
Fourth dose of COVID-19 vaccines in Israel	36
Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study	36
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised	36
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial	36
The role of antiviral treatment in the COVID-19 pandemic	36
Increased cardiovascular mortality in African Americans with COVID-19	36
Assessing the importance of interleukin-6 in COVID-19	36
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	35
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial	35
A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19	35
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	35
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study	35
The right place for IL-1 inhibition in COVID-19	35
COVID-19: Respiratory support outside the intensive care unit	34
Airway management for COVID-19: a move towards universal videolaryngoscope?	34

Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study	34
Identification of pathophysiological patterns for triage and respiratory support in COVID-19	34
Association between very to moderate preterm births, lung function deficits, and COPD at age 53 years: analysis of a prospective cohort study	34
Considerations for ventilator triage during the COVID-19 pandemic	33
Challenges in the rollout of COVID-19 vaccines worldwide	33
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study	33
Successful double-lung transplantation from a donor previously infected with SARS-CoV-2	33
Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials	33
Dynamic zero COVID policy in the fight against COVID	33
Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial	33
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	32
Post-tuberculosis mortality and morbidity: valuing the hidden epidemic	32
Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?	32
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial	32
Long COVID: aiming for a consensus	32
Tackling two pandemics: a plea on World Tuberculosis Day	32
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension	32
Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study	32
South America prepares for the impact of COVID-19	32
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study	32
Child poverty, food insecurity, and respiratory health during the COVID-19 pandemic	32
Testing for COVID-19	31
Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomi	31
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label	31
Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial	31
Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis	31
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	31
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	30
Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study	30
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial	30
Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial	30
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 tri	30
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dumm	30
Neutrophilic asthma: misconception or misnomer?	30
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	30
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	30
Antihypertensive drugs and risk of COVID-19? – Authors' reply	30
The EVALI outbreak and vaping in the COVID-19 era	29
GOLD report: 2022 update	29
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies	29
Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder	28
Effect of early parenteral nutrition during paediatric critical illness on DNA methylation as a potential mediator of impaired neurocognitive development: a pre-planned secondary analysis of the PEPaN	28
Antihypertensive drugs and risk of COVID-19?	28
POCUS in COVID-19: pearls and pitfalls	28
Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities	28
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial	27
Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-c	27
Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19	27
Nebulised interferon beta-1a for patients with COVID-19	27
Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research	27
GOLD COPD report: 2023 update	27